Comparison
NMN vs Alpha-Lipoic Acid
NMN
Nicotinamide mononucleotide — NAD+ precursor. Studied for cellular aging and metabolic health.
Alpha-Lipoic Acid
Universal antioxidant active in both lipid and aqueous environments. Supports mitochondrial function and AGE reduction.
| Field | NMN | Alpha-Lipoic Acid |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 300–600mg |
| Half-life | — | 1h |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 600 | 1900 |
The comparison in plain English
Auto-generated from dataNMN and Alpha-Lipoic Acid are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. Alpha-Lipoic Acid Universal antioxidant active in both lipid and aqueous environments.
Bottom line
NMN (evidence B, safety 5/5) has a stronger evidence base than Alpha-Lipoic Acid (evidence A, safety 4/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.
Choose Alpha-Lipoic Acid if
Alpha-Lipoic Acid is the better fit when your goal aligns with its mechanism (A 'universal' antioxidant — uniquely active in both lipid (cell membrane) and aqueous (cytoplasm) environments because of its dithiol functional group) and the dose range (300–600mg) suits your protocol. Half-life is 1h.